One-hundred and forty-nine consecutive AML patients, with NPM1, FLT3-ITD mutation or both, treated in three Hematology Italian centers from January 2008 to January 2018, were retrospectively included in this analysis. This evidence concerns the gene NPM1 and acute myeloid leukemia.